Neurocrine Biosciences CMO reports 51,331 shares
The listed awards include options exercisable at stated prices and restricted stock units with scheduled vesting dates through February 2029.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Neurocrine Biosciences (NBIX) Chief Medical Officer Eiry Roberts reported 51,331 shares of common stock as of September 28, 2026. Of those, 50,146 shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, over which Dr. Roberts has voting and investment power. The report also lists options over common shares, including 60,005 shares at a $79.02 exercise price, expiring January 31, 2032, and 2,114 restricted stock units scheduled to vest February 13, 2027, subject to award terms.
Insider Trade Summary
17 transactions reported
Mixed
17 txns
Insider
ROBERTS EIRY
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Non-Qualified Stock Option F2 | -- | -- | -- |
| holding | Non-Qualified Stock Option F3 | -- | -- | -- |
| holding | Non-Qualified Stock Option F4 | -- | -- | -- |
| holding | Incentive Stock Option F5 | -- | -- | -- |
| holding | Non-Qualified Stock Option F5 | -- | -- | -- |
| holding | Incentive Stock Option F6 | -- | -- | -- |
| holding | Non-Qualified Stock Option F6 | -- | -- | -- |
| holding | Non-Qualified Stock Option F7 | -- | -- | -- |
| holding | Incentive Stock Option F8 | -- | -- | -- |
| holding | Non-Qualified Stock Option F8 | -- | -- | -- |
| holding | Non-Qualified Stock Option F9 | -- | -- | -- |
| holding | Restricted Stock Unit F11, F10 | -- | -- | -- |
| holding | Restricted Stock Unit F11, F12 | -- | -- | -- |
| holding | Restricted Stock Unit F11, F13 | -- | -- | -- |
| holding | Restricted Stock Unit F11, F14 | -- | -- | -- |
| holding | Restricted Stock Unit F11, F15 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Non-Qualified Stock Option — 278,965 contracts (Direct);
Incentive Stock Option — 2,565 contracts (Direct);
Restricted Stock Unit — 16,129 contracts (Direct);
Common Stock — 51,331 shares (Direct)
Footnotes (15)
- F1. 50,146 of the outstanding shares are held by The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement, of which Dr. Roberts has voting and investment power.
- F2. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
- F3. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 8, 2021 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
- F4. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option became vested and exercisable each month thereafter.
- F5. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2023 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F6. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 13, 2024 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F7. Represents an option of which 1/4 of the shares underlying the option became vested and exercisable on February 13, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter beginning on March 13, 2025, such that the option shall fully vest on February 13, 2028.
- F8. Represents option of which 1/48th of the shares underlying the option became vested and exercisable on March 12, 2025 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F9. Represents option of which 1/12th of the shares underlying the option became vested and exercisable on March 13, 2026 and an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F10. Represents Restricted Stock Units (RSUs) remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 2,113 shares on February 13, 2024, vested as to 2,113 shares on February 13, 2025, vested as to 2,113 shares on February 13, 2026, and will vest as to 2,114 shares on February 13, 2027, subject to the terms and conditions of the award.
- F11. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
- F12. Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,120 shares on February 13, 2025, vested as to 1,121 shares on February 13, 2026, and will vest as to 1,121 shares on February 13, 2027, and 1,121 shares on February 13, 2028, subject to the terms and conditions of the award.
- F13. Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on December 17, 2024. In accordance with the terms of the RSU, the award vested as to 1,372 shares on February 13, 2025, vested as to 1,372 shares on February 13, 2026, and will vest as to 1,372 shares on February 13, 2027, and 1,371 shares on February 13, 2028, subject to the terms and conditions of the award.
- F14. Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 2,027 shares on February 12, 2026, and will vest as to 2,027 shares on February 12, 2027, 2,027 shares on February 12, 2028, and 2,027 shares on February 12, 2029, subject to the terms and conditions of the award.
- F15. Represents RSUs remaining outstanding as of September 28, 2026 under an RSU award granted to the Reporting Person on February 13, 2026. In accordance with the terms of the RSU, the award will vest in full as to 2,949 shares on February 13, 2027, subject to the terms and conditions of the award.
Key Figures
Common stock reported: 51,331 shares
Common stock held by joint trust: 50,146 shares
Non-Qualified Stock Option: 60,005 underlying shares; $79.02 exercise price
+3 more
6 metrics
Common stock reported
51,331 shares
As of September 28, 2026
Common stock held by joint trust
50,146 shares
Dr. Roberts has voting and investment power
Non-Qualified Stock Option
60,005 underlying shares; $79.02 exercise price
Expiration date: January 31, 2032
Non-Qualified Stock Option
48,199 underlying shares; $117.63 exercise price
Expiration date: February 8, 2031
Non-Qualified Stock Option
17,147 underlying shares; $102.90 exercise price
Expiration date: February 6, 2030
Restricted Stock Unit
6,081 units
Remaining outstanding as of September 28, 2026
Key Terms
Non-Qualified Stock Option, Incentive Stock Option, Restricted Stock Units (RSUs), vested and exercisable, +1 more
5 terms
Non-Qualified Stock Option financial
"Represents option"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Incentive Stock Option financial
"Incentive Stock Option"
An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.
Restricted Stock Units (RSUs) financial
"Represents Restricted Stock Units (RSUs) remaining outstanding"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
vested and exercisable financial
"became vested and exercisable"
contingent right financial
"Each RSU represents a contingent right to receive one share"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When do Eiry Roberts's 2023 NBIX restricted stock units vest?
The restricted stock unit award granted February 13, 2023, has 2,114 shares remaining as of September 28, 2026, scheduled to vest February 13, 2027, subject to the terms and conditions of the award. The award previously vested as to 2,113 shares on each of February 13, 2024, February 13, 2025, and February 13, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
